EMA/623415/2020

European Medicines Agency decision

P/0457/2020

of 4 December 2020

on the agreement of a paediatric investigation plan and on the granting of a waiver for venglustat (EMEA-001716-PIP04-19) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0457/2020

of 4 December 2020

on the agreement of a paediatric investigation plan and on the granting of a waiver for venglustat (EMEA-001716-PIP04-19) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Genzyme Europe B.V. on 28 November 2019 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 16 October 2020, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for venglustat, tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A waiver for venglustat, tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Genzyme Europe B.V., Paasheuvelweg 25, 1105 BP - Amsterdam, Netherlands.

EMA/PDCO/424867/2020
Amsterdam, 16 October 2020

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a waiver

EMEA-001716-PIP04-19

Scope of the application

Active substance(s):

Venglustat

Condition(s):

Treatment of GM2 gangliosidosis

Treatment of GM1 gangliosidosis

Treatment of galactosialidosis

Treatment of sialidosis

Pharmaceutical form(s):

Tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Genzyme Europe B.V.

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Genzyme Europe B.V. submitted for agreement to the European Medicines Agency on 28 November 2019 an application for a paediatric investigation plan for the above mentioned medicinal product and a waiver under Article 13 of said Regulation.

The procedure started on 6 January 2020.

Supplementary information was provided by the applicant on 10 July 2020. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(a) of said Regulation, on the grounds that the specific medicinal product is likely to be ineffective or unsafe in part or all of the paediatric population.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of GM2 gangliosidosis

The waiver applies to:

- all subsets of the paediatric population from birth to less than 2 years of age;
- tablet, oral use;
- on the grounds that the specific medicinal product is likely to be ineffective.

1.2. Condition:

Treatment of GM1 gangliosidosis

The waiver applies to:

- all subsets of the paediatric population from birth to less than 2 years of age;
- tablet, oral use;
- on the grounds that the specific medicinal product is likely to be ineffective.

1.3. Condition:

Treatment of galactosialidosis

The waiver applies to:

- all subsets of the paediatric population from birth to less than 2 years of age;
- tablet, oral use;
- on the grounds that the specific medicinal product is likely to be ineffective.

1.4. Condition:

Treatment of sialidosis

The waiver applies to:

- all subsets of the paediatric population from birth to less than 2 years of age;
- tablet, oral use;
- on the grounds that the specific medicinal product is likely to be ineffective.

2. Paediatric investigation plan

2.1. Condition:

Treatment of GM2 gangliosidosis

2.1.1. Indication(s) targeted by the PIP

Long term treatment of patients from 2 years of age to less than 18 years of age with juvenile (subacute) and adolescent (late-onset) GM2 gangliosidosis

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years of age to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Tablet

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	2	**Study 1** Development of small size chewable tablets of 4 mg, 6 mg and 15 mg dosage strengths appropriate to be administered in paediatric patients from 2 years of age and older using doses based on body weight **Study 2** Generation of data in adult subjects on the palatability of the tablets (ACC15856)
Non-clinical studies	1	**Study 3** Enhanced pre- and postnatal development study in Sprague-Dawley rats to evaluate the potential toxic effects of venglustat on the pregnant/lactating female and on development of the conceptus and the offspring through sexual maturity
Clinical studies	1	**Study 4** Randomised, double-blind, placebo-controlled study to evaluate the efficacy, pharmacokinetics, pharmacodynamics, safety and tolerability of venglustat in adult patients with (late onset) GM2 gangliosidosis (primary population) with an open-label single-arm part to evaluate the efficacy, pharmacokinetics, pharmacodynamics, safety and tolerability of venglustat in paediatric patients from 2 years to less than 18 years of age with (juvenile and late onset) GM2 gangliosidosis, GM1 gangliosidosis, galactosialidosis and sialidosis (secondary population) (EFC15299 - AMETHIST)
Extrapolation, modelling and simulation studies	1	**Study 5** Modelling and simulation study to determine the dose of venglustat to be used in the paediatric population from 2 years of age to less than

		18 years of age (SIM0452)
Other studies	0	Not applicable.
Other measures	0	Not applicable.

2.2. Condition:

Treatment of GM1 gangliosidosis

2.2.1. Indication(s) targeted by the PIP

Long term treatment of patients from 2 years of age to less than 18 years of age with GM1 gangliosidosis

2.2.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years of age to less than 18 years of age

2.2.3. Pharmaceutical form(s)

Tablet

2.2.4. Measures

Area	**Number of measures**	**Description**
Quality-related studies	2	**Study 1** (same as study 1 for the condition treatment of GM2 gangliosidosis) **Study 2** (same as study 2 for the condition treatment of GM2 gangliosidosis)
Non-clinical studies	1	**Study 3** (same as study 3 for the condition treatment of GM2 gangliosidosis)
Clinical studies	1	**Study 4** (same as study 4 for the condition treatment of GM2 gangliosidosis)
Extrapolation, modelling and simulation studies	1	**Study 5** (same as study 5 for the condition treatment of GM2 gangliosidosis)
Other studies	0	Not applicable.
Other measures	0	Not applicable.

2.3. Condition:

Treatment of galactosialidosis

2.3.1. Indication(s) targeted by the PIP

Long term treatment of patients from 2 years of age to less than 18 years of age with galactosialidosis

2.3.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years of age to less than 18 years of age

2.3.3. Pharmaceutical form(s)

Tablet

2.3.4. Measures

Area	Number of measures	Description
Quality-related studies	2	**Study 1** (same as study 1 for the condition treatment of GM2 gangliosidosis) **Study 2** (same as study 2 for the condition treatment of GM2 gangliosidosis)
Non-clinical studies	1	**Study 3** (same as study 3 for the condition treatment of GM2 gangliosidosis)
Clinical studies	1	**Study 4** (same as study 4 for the condition treatment of GM2 gangliosidosis)
Extrapolation, modelling and simulation studies	1	**Study 5** (same as study 5 for the condition treatment of GM2 gangliosidosis)
Other studies	0	Not applicable.
Other measures	0	Not applicable.

2.4. Condition:

Treatment of sialidosis

2.4.1. Indication(s) targeted by the PIP

Long term treatment of patients from 2 years of age to less than 18 years of age with sialidosis

2.4.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years of age to less than 18 years of age

2.4.3. Pharmaceutical form(s)

Tablet

2.4.4. Measures

Area	Number of measures	Description
Quality-related studies	2	**Study 1** (same as study 1 for the condition treatment of GM2 gangliosidosis) **Study 2** (same as study 2 for the condition treatment of GM2 gangliosidosis)
Non-clinical studies	1	**Study 3** (same as study 3 for the condition treatment of GM2 gangliosidosis)
Clinical studies	1	**Study 4** (same as study 4 for the condition treatment of GM2 gangliosidosis)
Extrapolation, modelling and simulation studies	1	**Study 5** (same as study 5 for the condition treatment of GM2 gangliosidosis)
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By May 2024
Deferral for one or more measures contained in the paediatric investigation plan:	No